New Long-Term Data from the CHRYSALIS Study Show Median Progression-Free Survival Not Reached after 33.6 Months of Follow-Up with First-Line Use of RYBREVANT ® (amivantamab-vmjw) and Lazertinib Combination Therapy in Patients with Treatment-Naïve EGFR-Mutated Advanced Non-Small Cell Lung Cancer

CHICAGO, June 4, 2023– The Janssen Pharmaceutical Companies of Johnson& Johnson today announced long-term results from the CHRYSALIS study, which showed the combination of RYBREVANT® (amivantamab-vmjw) and lazertinib*, a...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials